Nifedipine
- Generic Name
- Nifedipine
- Brand Names
- Adalat, Afeditab CR, Nifediac, Nifedical, Procardia
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N2O6
- CAS Number
- 21829-25-4
- Unique Ingredient Identifier
- I9ZF7L6G2L
- Background
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine. Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is amlodipine.
Nifedipine was granted FDA approval on 31 December 1981.
- Indication
Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.
- Associated Conditions
- Achalasia, Chronic Stable Angina Pectoris, Fissure;Anal, Hypertension, Hypertensive Emergency, Premature Labour, Proctalgia, Pulmonary Edemas, Pulmonary Hypertension (PH), Raynaud's Phenomenon, Ureteral Calculus, Vasospastic Angina
Treatment of Hypertension With Adalat® in Combination With Other Drugs
- First Posted Date
- 2010-05-06
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4497
- Registration Number
- NCT01118286
FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 365
- Registration Number
- NCT01071122
Amlodipine Prevents Morning Blood Pressure Surge Study
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 510
- Registration Number
- NCT01030081
- Locations
- 🇨🇳
Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
The Pharmacokinetics of Nifedipine Controlled Release Tablets in Hypertensive Patients on Hemodialysis
- Conditions
- Hypertension on Chronic Maintenance Hemodialysis
- Interventions
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2009-11-30
- Lead Sponsor
- Guangzhou First People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT01021501
- Locations
- 🇨🇳
Department of Nephrology, Guangzhou First Municipal People's Hospital, Guangzhou, Guangdong, China
Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2014-06-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 360
- Registration Number
- NCT00993109
An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2011-02-16
- Lead Sponsor
- RDD Pharma Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT00972907
- Locations
- 🇮🇱
Sapir Medical Center, Kfar Saba, Israel
🇮🇱Macabi HMO, Tel Aviv, Israel
Nifedipine Bioavailability Study With Oral Single Doses Under Fasting and Fed Conditions
- Conditions
- Bioavailability, Therapeutical Indication Not Studied
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2009-10-21
- Lead Sponsor
- SocraTec R&D GmbH
- Target Recruit Count
- 28
- Registration Number
- NCT00884442
- Locations
- 🇩🇪
SocraTec R&D Probandenstation, Erfurt, Thüringen, Germany
A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2010-08-17
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT00865891
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2010-08-17
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT00864617
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Sitaxsentan in Proteinuric Chronic Kidney Disease
- Conditions
- Chronic Kidney DiseaseProteinuriaBlood Pressure
- Interventions
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 27
- Registration Number
- NCT00817037
- Locations
- 🇬🇧
Clinical Research Centre, Western General Hospital, Edinburgh, Scotland, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.